Trial Profile
A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Jan 2010 New trial record